Immunohistochemistry in Veterinary Tumor Diagnosis

Immunohistochemistry uses labeled antibodies on tissue sections to help classify tumors or investigate specific markers after morphology has been reviewed.

A pathologist applies a selected antibody panel to fixed tissue and interprets the staining pattern, location, controls, and morphology. The best panel depends on the differential diagnosis and specimen quality rather than a universal cancer panel.

IHC can help distinguish tumor lineages, refine a diagnosis, or assess selected prognostic or treatment-related markers. It often follows routine histopathology when appearance alone does not resolve the question.

Its value is highest when the result answers a defined question and would change diagnosis, staging, treatment, anesthesia, supportive care, or the recheck plan. Testing without a decision pathway can add cost or uncertainty without helping the patient.

The veterinary team selects timing, sample type, preparation, laboratory or imaging method, and repetition interval for the individual patient. Ask how this result will be interpreted alongside examination findings, pathology, prior results, medicines, and current symptoms.

IHC is established in veterinary anatomic pathology, but antibody validation, tissue fixation, tumor heterogeneity, cutoff selection, and marker-specific evidence limit what a stain can prove. A marker is not automatically a treatment prediction.

There is usually no added patient procedure when stored tissue is sufficient. The risks are added cost, tissue exhaustion, delay, and overinterpreting an imperfect or nonspecific stain without appropriate controls.

A normal result cannot rule out every tumor or complication, and an abnormal result does not by itself identify the cause. Collection quality, timing, prior treatment, sedation, and laboratory or operator variation can affect interpretation.